Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2017’, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)

The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects

The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actuate Therapeutics Inc

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced Cancer Therapeutics LLC

Advenchen Laboratories LLC

Affitech A/S

Alethia Biotherapeutics Inc

Alkermes Plc

Altor BioScience Corp

Ambrx Inc

Amgen Inc

Ampio Pharmaceuticals Inc

Apac Biotech Pvt Ltd

Apcure SAS

APEIRON Biologics AG

Aphios Corp

arGEN-X BV

Argos Therapeutics Inc

ARMO Biosciences Inc

ArQule Inc

Arrowhead Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BeiGene (Beijing) Co Ltd

Berg LLC

Bio-Cancer Treatment International Ltd

Biocad

Bionomics Ltd

Bionovis SA

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellular Biomedicine Group Inc

Celyad SA

Chipscreen Biosciences Ltd

Cleave Biosciences Inc

COARE Biotechnology Inc

Coherus BioSciences Inc

Corvus Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Company

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

Genentech Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Glycotope GmbH

Hemispherx Biopharma Inc

HitGen LTD

Horizon Pharma Plc

Hutchison China MediTech Ltd

Ignyta Inc

Immune Design Corp

Immune Pharmaceuticals Inc

Immunicum AB

ImmunoFrontier Inc

ImmunoGen Inc

Immunomedics Inc

Immunomet Therapeutics Inc

Incyte Corp

Innate Immunotherapeutics Ltd

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Johnson & Johnson

KAHR medical Ltd

Karyopharm Therapeutics Inc

KineMed Inc

Kite Pharma Inc

Komipharm International Co Ltd

Konruns Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Lidds AB

Lion Biotechnologies Inc

Mabion SA

MacroGenics Inc

Mantis Therapeutics BV

MaxiVAX SA

MedImmune LLC

Medinet Co Ltd

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Molecular Partners AG

Moleculin Biotech Inc

Monopar Therapeutics LLC

Mount Tam Biotechnologies Inc

Mycenax Biotech Inc

NanoSmart Pharmaceuticals Inc

NantKwest Inc

NBE-Therapeutics AG

Nektar Therapeutics

NewLink Genetics Corp

Novartis AG

NovaTarg Therapeutics Inc

Omeros Corp

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncogenex Pharmaceuticals Inc

Oncolys BioPharma Inc

OncoMax

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Peloton Therapeutics Inc

Pfizer Inc

Pharma Mar SA

Pharmicell Co Ltd

Pivotal BioSciences Inc

Plexxikon Inc

Prima BioMed Ltd

PsiOxus Therapeutics Ltd

Recombio SL

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Sanofi

Selvita SA

Sevion Therapeutics Inc

Sillajen Biotherapeutics

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Systimmune Inc

Taiwan Liposome Company Ltd

Taris Biomedical LLC

TC BioPharm Ltd

Tocagen Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

TVAX Biomedical Inc

Tyrogenex Inc

UroGen Pharmaceuticals Ltd

Valeant Pharmaceuticals International Inc

Vascular Biogenics Ltd

Vault Pharma Inc

Vaxeal Holding SA

ViiV Healthcare Ltd

X4 Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Kidney Cancer (Renal Cell Cancer) - Overview 10

Kidney Cancer (Renal Cell Cancer) - Therapeutics Development 11

Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 48

Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 72

Kidney Cancer (Renal Cell Cancer) - Drug Profiles 157

Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1233

Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1246

Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1249

Appendix 1265

List of Tables

List of Tables

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by 4SC AG, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by AbbVie Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Actuate Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aduro BioTech Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Advanced Cancer Therapeutics LLC, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Advenchen Laboratories LLC, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Affitech A/S, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Alethia Biotherapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Alkermes Plc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Altor BioScience Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ambrx Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Amgen Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ampio Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Apac Biotech Pvt Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Apcure SAS, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by APEIRON Biologics AG, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aphios Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by arGEN-X BV, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Argos Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by ARMO Biosciences Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by ArQule Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Astellas Pharma Inc, H1 2017

ney Cancer (Renal Cell Cancer) – Pipeline by AstraZeneca Plc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bayer AG, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Berg LLC, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Biocad, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bionomics Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bionovis SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Boston Biomedical Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Calithera Biosciences Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by CASI Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by CBT Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Celgene Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Celldex Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Celyad SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Cleave Biosciences Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by COARE Biotechnology Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Coherus BioSciences Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Corvus Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ecrins Therapeutics SAS, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Eisai Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Eli Lilly and Company, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Exelixis Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Gene Techno Science Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Genentech Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Genor BioPharma Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by GlaxoSmithKline Plc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Glycotope GmbH, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Hemispherx Biopharma Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by HitGen LTD, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Horizon Pharma Plc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Hutchison China MediTech Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ignyta Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immune Design Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immunicum AB, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by ImmunoFrontier Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by ImmunoGen Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immunomedics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immunomet Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Incyte Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Innate Immunotherapeutics Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Inspyr Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Johnson & Johnson, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by KAHR medical Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by KineMed Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Kite Pharma Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Komipharm International Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Konruns Pharmaceutical Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Lead Discovery Center GmbH, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Lidds AB, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Lion Biotechnologies Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mabion SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by MacroGenics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mantis Therapeutics BV, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by MaxiVAX SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by MedImmune LLC, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Medinet Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Merck & Co Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Merck KGaA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mirati Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Molecular Partners AG, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Moleculin Biotech Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Monopar Therapeutics LLC, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mount Tam Biotechnologies Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mycenax Biotech Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by NantKwest Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by NBE-Therapeutics AG, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Nektar Therapeutics, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by NewLink Genetics Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Novartis AG, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by NovaTarg Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Omeros Corp, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncobiologics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncolys BioPharma Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by OncoMax, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by OncoTherapy Science Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncovir Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Peloton Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pfizer Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharma Mar SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharmicell Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pivotal BioSciences Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Plexxikon Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Prima BioMed Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by PsiOxus Therapeutics Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Recombio SL, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Richter Gedeon Nyrt, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sanofi, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Selvita SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sevion Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sillajen Biotherapeutics, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sorrento Therapeutics Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Synthon Holdings BV, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Systimmune Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Taris Biomedical LLC, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by TC BioPharm Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Tocagen Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by TVAX Biomedical Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Tyrogenex Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by UroGen Pharmaceuticals Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Valeant Pharmaceuticals International Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vascular Biogenics Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vault Pharma Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vaxeal Holding SA, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by ViiV Healthcare Ltd, H1 2017

Kidney Cancer (Renal Cell Cancer) – Pipeline by X4 Pharmaceuticals Inc, H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..4), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..5), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..6), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..7), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..8), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..9), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..10), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..11), H1 2017

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H1 2017 (Contd..12), H1 2017

Kidney Cancer (Renal Cell Cancer) – Discontinued Products, H1 2017

Kidney Cancer (Renal Cell Cancer) – Discontinued Products, H1 2017 (Contd..1), H1 2017

Kidney Cancer (Renal Cell Cancer) – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports